arrow
N

Noriyuki Namba

Tottori University
H指数:33
被引数:7,429

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Earlier bedtime at 1.5 years is associated with greater height gain at 3 years of age: a nationwide birth cohort study of the Japan environment and children’s study

1.5岁时较早的入睡时间与3岁时的身高增长更大相关:日本环境与儿童研究的全国性出生队列研究

2026-09-270
OA
A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of vosoritide in children with hypochondroplasia: CANOPY HCH-3 study design

III期、随机、双盲、安慰剂对照、多中心研究,旨在评估vosoritide在软骨发育不全儿童中的有效性和安全性:CANOPY HCH-3研究设计

2026-09-020
PRE
Diagnosis of hypochondroplasia: international Delphi consensus recommendations

软骨发育不全的诊断:国际德尔菲共识建议

2026-08-200
PRE
Transient Oxygen Desaturation Associated with Persistent Right Venous Valve-Mediated Right-to-Left Atrial Shunt in Term Neonates

与持续性右心静脉瓣介导的右向左心房分流相关的足月新生儿短暂性血氧饱和度下降

2026-05-010
PRE
Distribution of blood pressure and its positive association with body mass index standard deviation score in pediatric patients with X-linked hypophosphatemia: a sub-group analysis from the SUNFLOWER observational study

X-连锁低磷酸盐血症儿科患者中血压分布及其与体重指数标准差评分的正相关关系:SUNFLOWER观察性研究的亚组分析

2025-10-010
OAAI
Impact of X-linked hypophosphatemic rickets/osteomalacia on health and quality of life: baseline data from the SUNFLOWER longitudinal, observational cohort study

X连锁低血磷性佝偻病/骨软化症对健康和生活质量的影响: 向日葵纵向观察队列研究的基线数据

2024-09-101
OAAI
Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension period

Burosumab与X连锁低磷血症患儿的常规治疗: 开放标签,3期延长期的结果

2024-01-043
OAAI
Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level

Burosumab与磷酸盐/活性维生素d在小儿X连锁低磷血症中的作用: 剂量水平的亚组分析

2023-04-219
OA
Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia

与常规疗法相比,Burosumab对X连锁低磷血症的年龄较小和年龄较大的儿童的影响

2022-05-0945
OA
Genotype-phenotype analysis, and assessment of the importance of the zinc-binding site in PHEX in Japanese patients with X-linked hypophosphatemic rickets using 3D structure modeling
BONE
IF3.6
2021-12-0115
OAAI
Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia
2021-01-2331
OAAI